Benoît Van Den Eynde

Title: The Innovative Contributions of Benoît Van Den Eynde

Introduction

Benoît Van Den Eynde is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer treatment through his innovative research and development of immunogenic compositions. His work focuses on utilizing recombinant proteins to enhance therapeutic options for patients suffering from melanoma.

Latest Patents

Benoît Van Den Eynde holds a patent for an immunogenic composition that comprises a recombinant protein featuring aCyaA or a fragment thereof, along with a peptide corresponding to a tumor antigen. This composition is designed as a cancer treatment, specifically targeting melanoma. The therapeutic composition includes epitopes from the HLA*0201 epitope, which are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V. He has 1 patent related to this groundbreaking work.

Career Highlights

Throughout his career, Benoît has worked with prestigious institutions such as the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale. His research has contributed to advancements in immunotherapy and has the potential to improve treatment outcomes for cancer patients.

Collaborations

Benoît has collaborated with esteemed colleagues, including Gilles Dadaglio and Claude Leclerc. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer treatments.

Conclusion

Benoît Van Den Eynde's contributions to cancer treatment through his patented immunogenic compositions highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in therapeutic options for melanoma patients.